Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
2737 | 2161 | 34.8 | 81% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
7 | 4 | INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY | 1353914 |
73 | 3 | MICROBIOLOGY//INFECTIOUS DISEASES//STAPHYLOCOCCUS AUREUS | 82747 |
575 | 2 | VANCOMYCIN//LINEZOLID//DAPTOMYCIN | 14274 |
2737 | 1 | DAPTOMYCIN//HVISA//VANCOMYCIN | 2161 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | DAPTOMYCIN | authKW | 3340632 | 17% | 66% | 358 |
2 | HVISA | authKW | 404882 | 2% | 87% | 33 |
3 | VANCOMYCIN | authKW | 307229 | 10% | 10% | 225 |
4 | VISA | authKW | 275045 | 2% | 43% | 45 |
5 | ANTIINFECT | address | 221654 | 3% | 23% | 67 |
6 | GRAM POSITIVE INFECTIONS | authKW | 187688 | 2% | 39% | 34 |
7 | MOL GENET ANTIMICROBIAL ISTANCE UNIT | address | 140992 | 1% | 43% | 23 |
8 | DAPTOMYCIN RESISTANCE | authKW | 131500 | 1% | 85% | 11 |
9 | MIC CREEP | authKW | 131500 | 1% | 85% | 11 |
10 | MRSA | authKW | 130884 | 8% | 5% | 170 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Infectious Diseases | 45228 | 43% | 0% | 929 |
2 | Microbiology | 44957 | 60% | 0% | 1289 |
3 | Pharmacology & Pharmacy | 11715 | 43% | 0% | 937 |
4 | Immunology | 578 | 10% | 0% | 207 |
5 | Medicine, General & Internal | 222 | 6% | 0% | 138 |
6 | Critical Care Medicine | 18 | 1% | 0% | 20 |
7 | Medical Laboratory Technology | 14 | 1% | 0% | 15 |
8 | Biotechnology & Applied Microbiology | 10 | 3% | 0% | 55 |
9 | Chemistry, Medicinal | 3 | 1% | 0% | 25 |
10 | Pediatrics | 3 | 1% | 0% | 32 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANTIINFECT | 221654 | 3% | 23% | 67 |
2 | MOL GENET ANTIMICROBIAL ISTANCE UNIT | 140992 | 1% | 43% | 23 |
3 | EUGENE PLEBAUM PHARM HLTH SCI | 87656 | 3% | 10% | 61 |
4 | INT MICROBIAL GENOM | 63575 | 0% | 75% | 6 |
5 | AUSTIN INFECT | 40715 | 0% | 41% | 7 |
6 | INFECT DIS | 38971 | 21% | 1% | 461 |
7 | ANTI INFECT | 35674 | 1% | 21% | 12 |
8 | ANTIBIOT ISTANCE MOBILE ELEMENTS GRP | 34606 | 0% | 35% | 7 |
9 | ANTIMICROBIAL PHARMACODYNAM | 32684 | 0% | 26% | 9 |
10 | PAEDIAT PATHOL MOL BIOMED SCI | 31787 | 0% | 75% | 3 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 82422 | 17% | 2% | 371 |
2 | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 34168 | 8% | 1% | 174 |
3 | INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 30506 | 4% | 2% | 91 |
4 | CLINICAL MICROBIOLOGY AND INFECTION | 11233 | 3% | 1% | 57 |
5 | EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 10620 | 3% | 1% | 69 |
6 | DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 10458 | 3% | 1% | 63 |
7 | REVISTA ESPANOLA DE QUIMIOTERAPIA | 10357 | 1% | 4% | 17 |
8 | CLINICAL INFECTIOUS DISEASES | 9008 | 4% | 1% | 91 |
9 | JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE | 6232 | 0% | 4% | 10 |
10 | JOURNAL OF INFECTION AND CHEMOTHERAPY | 4476 | 1% | 2% | 19 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | DAPTOMYCIN | 3340632 | 17% | 66% | 358 | Search DAPTOMYCIN | Search DAPTOMYCIN |
2 | HVISA | 404882 | 2% | 87% | 33 | Search HVISA | Search HVISA |
3 | VANCOMYCIN | 307229 | 10% | 10% | 225 | Search VANCOMYCIN | Search VANCOMYCIN |
4 | VISA | 275045 | 2% | 43% | 45 | Search VISA | Search VISA |
5 | GRAM POSITIVE INFECTIONS | 187688 | 2% | 39% | 34 | Search GRAM+POSITIVE+INFECTIONS | Search GRAM+POSITIVE+INFECTIONS |
6 | DAPTOMYCIN RESISTANCE | 131500 | 1% | 85% | 11 | Search DAPTOMYCIN+RESISTANCE | Search DAPTOMYCIN+RESISTANCE |
7 | MIC CREEP | 131500 | 1% | 85% | 11 | Search MIC+CREEP | Search MIC+CREEP |
8 | MRSA | 130884 | 8% | 5% | 170 | Search MRSA | Search MRSA |
9 | GISA | 125660 | 1% | 68% | 13 | Search GISA | Search GISA |
10 | STAPHYLOCOCCUS AUREUS | 117916 | 13% | 3% | 276 | Search STAPHYLOCOCCUS+AUREUS | Search STAPHYLOCOCCUS+AUREUS |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | HOWDEN, BP , DAVIES, JK , JOHNSON, PDR , STINEAR, TP , GRAYSON, ML , (2010) REDUCED VANCOMYCIN SUSCEPTIBILITY IN STAPHYLOCOCCUS AUREUS, INCLUDING VANCOMYCIN-INTERMEDIATE AND HETEROGENEOUS VANCOMYCIN-INTERMEDIATE STRAINS: RESISTANCE MECHANISMS, LABORATORY DETECTION, AND CLINICAL IMPLICATIONS.CLINICAL MICROBIOLOGY REVIEWS. VOL. 23. ISSUE 1. P. 99-+ | 201 | 59% | 312 |
2 | HUMPHRIES, RM , POLLETT, S , SAKOULAS, G , (2013) A CURRENT PERSPECTIVE ON DAPTOMYCIN FOR THE CLINICAL MICROBIOLOGIST.CLINICAL MICROBIOLOGY REVIEWS. VOL. 26. ISSUE 4. P. 759-780 | 151 | 79% | 48 |
3 | TRAN, TT , MUNITA, JM , ARIAS, CA , (2015) MECHANISMS OF DRUG RESISTANCE: DAPTOMYCIN RESISTANCE.ANTIMICROBIAL THERAPEUTICS REVIEWS. VOL. 1354. ISSUE . P. 32 -53 | 115 | 83% | 8 |
4 | TAYLOR, SD , PALMER, M , (2016) THE ACTION MECHANISM OF DAPTOMYCIN.BIOORGANIC & MEDICINAL CHEMISTRY. VOL. 24. ISSUE 24. P. 6253 -6268 | 90 | 85% | 1 |
5 | SENNEVILLE, E , CAILLON, J , CALVET, B , JEHL, F , (2016) TOWARDS A DEFINITION OF DAPTOMYCIN OPTIMAL DOSE: LESSONS LEARNED FROM EXPERIMENTAL AND CLINICAL DATA.INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. VOL. 47. ISSUE 1. P. 12 -19 | 67 | 93% | 2 |
6 | VAN HAL, SJ , JENSEN, SO , VASKA, VL , ESPEDIDO, BA , PATERSON, DL , GOSBELL, IB , (2012) PREDICTORS OF MORTALITY IN STAPHYLOCOCCUS AUREUS BACTEREMIA.CLINICAL MICROBIOLOGY REVIEWS. VOL. 25. ISSUE 2. P. 362 -386 | 125 | 43% | 116 |
7 | STEFANI, S , CAMPANILE, F , SANTAGATI, M , MEZZATESTA, ML , CAFISO, V , PACINI, G , (2015) INSIGHTS AND CLINICAL PERSPECTIVES OF DAPTOMYCIN RESISTANCE IN STAPHYLOCOCCUS AUREUS: A REVIEW OF THE AVAILABLE EVIDENCE.INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. VOL. 46. ISSUE 3. P. 278 -289 | 73 | 83% | 8 |
8 | BAYER, AS , SCHNEIDER, T , SAHL, HG , (2013) MECHANISMS OF DAPTOMYCIN RESISTANCE IN STAPHYLOCOCCUS AUREUS: ROLE OF THE CELL MEMBRANE AND CELL WALL.ANTIMICROBIAL THERAPEUTICS REVIEWS: THE BACTERIAL CELL WALL AS AN ANTIMICROBIAL TARGET. VOL. 1277. ISSUE . P. 139-158 | 73 | 67% | 71 |
9 | HOWDEN, BP , PELEG, AY , STINEAR, TP , (2014) THE EVOLUTION OF VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS (VISA) AND HETEROGENOUS-VISA.INFECTION GENETICS AND EVOLUTION. VOL. 21. ISSUE . P. 575-582 | 61 | 87% | 20 |
10 | GONZALEZ-RUIZ, A , SEATON, RA , HAMED, K , (2016) DAPTOMYCIN: AN EVIDENCE-BASED REVIEW OF ITS ROLE IN THE TREATMENT OF GRAM-POSITIVE INFECTIONS.INFECTION AND DRUG RESISTANCE. VOL. 9. ISSUE . P. 47 -58 | 83 | 72% | 0 |
Classes with closest relation at Level 1 |